Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Search content at Johns Hopkins University
Home
Profiles
Research units
Research output
Kidney damage in 'benign' essential hypertension
Paul K. Whelton
, Jiang He
, Thomas V. Perneger
, Michael J. Klag
School of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
24
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Kidney damage in 'benign' essential hypertension'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Kidney Injury
100%
Renal Disease
100%
Essential Hypertension
100%
Blood Pressure
75%
Renal Insufficiency
25%
Hypertension Management
25%
Antihypertensive Therapy
25%
High Blood Pressure
25%
Systolic Blood Pressure
25%
Diastolic Blood Pressure
25%
Strong Predictor
25%
Etiology
25%
Treatment Effect
25%
Beneficial Effects
25%
Risk Prediction
25%
Clinical Trials
25%
Renal Failure
25%
Ongoing Trials
25%
Angiotensin-converting Enzyme Inhibitor (ACEi)
25%
Type 2 Diabetic Patients
25%
Renal Damage
25%
New Guidelines
25%
Trial Experience
25%
Renal Morbidity
25%
Damage Progression
25%
Medicine and Dentistry
Nephropathy
100%
Kidney Injury
100%
Essential Hypertension
100%
Blood Pressure
75%
Renal Failure
50%
Hypertension
50%
Diastolic Blood Pressure
25%
Systolic Blood Pressure
25%
Antihypertensive Agent
25%
Observational Study
25%
Clinician
25%
Clinical Trial
25%
Morbidity
25%
Patient with Type 2 Diabetes
25%
ACE Inhibitor
25%
Etiology
25%
Nursing and Health Professions
Kidney Injury
100%
Kidney Disease
100%
Essential Hypertension
100%
Blood Pressure
75%
Kidney Failure
50%
Hypertension
50%
Practice Guideline
25%
Diastolic Blood Pressure
25%
Antihypertensive Agent
25%
Systolic Blood Pressure
25%
Patient with Type 2 Diabetes
25%
Dipeptidyl Carboxypeptidase Inhibitor
25%
Morbidity
25%
Etiology
25%
Clinical Trial
25%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Disease
100%
Kidney Injury
100%
Essential Hypertension
100%
Kidney Failure
50%
Hypertension
50%
Clinical Trial
25%
Antihypertensive Agent
25%
Observational Study
25%
Dipeptidyl Carboxypeptidase Inhibitor
25%
Morbidity
25%
Etiology
25%
Maturity Onset Diabetes of the Young
25%
Neuroscience
Hypertension
100%
ACE Inhibitor
33%
Antihypertensive Agent
33%